Turning Point Therapeutics (NASDAQ:TPTX) stock declared change of 134.70% away from 52-week low price and recently located move of -15.87% off 52-week high price. It has market worth of $2.34B. TPTX stock has been recorded 5.75% away from 50 day moving average and 30.88% away from 200 day moving average. Moving closer, we can see that shares have been trading -6.78% off 20-day moving average.
On Jan. 6, 2020, Turning Point Therapeutics (NASDAQ:TPTX) a precision oncology company developing next-generation therapies that target genetic drivers of cancer, named Homa Yeganegi as senior vice president, project team leader and head of Medical Affairs.
In this role, Ms. Yeganegi will lead the global product development team responsible for Turning Point Therapeutics’ lead drug candidate, repotrectinib, and as head of Medical Affairs will support the ongoing physician education associated with the company’s three clinical-stage drug candidates in four ongoing clinical studies. Ms. Yeganegi will report to President and Chief Executive Officer Athena Countouriotis, M.D.
Homa is a proven and strategic leader with deep experience in oncology drug development and commercial readiness, including supporting physician education and product development for large, global oncology indications, said Dr. Countouriotis. She is the ideal leader for our cross-function development team for repotrectinib and a valuable addition to our leadership team.
Ms. Yeganegi has extensive experience building and leading oncology-focused global Medical Affairs teams, most recently as senior vice president and global program leader at Halozyme, where she was responsible for commercialization strategy and operational planning for the company’s investigational oncology drug candidate. Ms. Yeganegi previously served as vice president of Global Medical Affairs at Clovis Oncology where she successfully supported pre-launch activities for rociletinib in non-small lung cancer in the U.S. and Europe. She also built and led oncology-focused Global Medical Affairs teams at Exelixis and Onyx Pharmaceuticals.
The Healthcare sector company, Turning Point Therapeutics noticed change of -13.05% to $56.82 along volume of 1309746 shares in recent session compared to an average volume of 484.52K. The stock observed return of -7.56% in 5 days trading activity. The stock was at 6.29% over one month performance. TPTX’s shares are at 54.07% for the quarter is now at -8.78% since this point in 2018.
The average volatility for the week at 8.38% and for month was at 6.04%. There are 41.23M shares outstanding and 33.29M shares are floated in market.